A UK clinical study testing a new way to examine the biology of coronary artery disease has passed its 100-patient milestone and expanded to eight specialist NHS cardiac centres.
The BIOPATTERN trial uses an intracoronary Liquid Biopsy System, or LBS, to collect blood directly from the area around coronary plaques during an already planned heart procedure.
Instead of relying only on blood drawn from the arm, researchers are trying to capture molecular signals close to the diseased artery itself.
The goal is ambitious: determine whether the biological processes driving coronary artery disease differ enough between patients to eventually support more personalized treatments.
According to the UK Health Research Authority’s BIOPATTERN study record, the study is designed to recruit 300 adults with established coronary artery disease and evaluate whether the Liquid Biopsy System can reliably collect disease-related biomolecules from coronary arteries.
The latest milestone does not mean the technology has been proven to prevent heart attacks or improve survival. The study is still focused on device performance, biomarker discovery and disease characterization.
Table of Contents
What BIOPATTERN Is Trying to Discover
Coronary artery disease develops when atherosclerotic plaque builds up inside the arteries supplying blood to the heart.
Over time, plaques can narrow arteries or become unstable and rupture.
A ruptured plaque can trigger formation of a blood clot capable of blocking blood flow and causing a heart attack.
Current treatment can substantially reduce that risk through:
- cholesterol-lowering therapy;
- blood-pressure management;
- antiplatelet medication;
- lifestyle modification;
- coronary intervention when necessary.
But patients with apparently similar coronary disease can still experience very different outcomes.
Some continue to have cardiovascular events despite receiving appropriate treatment.
Researchers refer to this as residual cardiovascular risk.
BIOPATTERN is investigating whether part of that residual risk can be explained by biological differences occurring directly inside diseased coronary arteries.
Why Draw Blood Directly From a Coronary Plaque?
Most biomarker testing starts with a blood sample from a vein in the arm.
That blood contains molecules circulating throughout the body.
A signal generated by a small but highly inflamed coronary plaque may therefore become diluted among thousands of proteins and other molecules originating from other organs.
BIOPATTERN takes a different approach.
During a planned coronary procedure, the Liquid Biopsy System collects blood from the artery around the region of disease.
Researchers can then compare concentrations of biomolecules and look for changes associated specifically with the plaque.
The idea is similar to examining the biological environment at the site of disease rather than measuring only systemic signals.
The Trial Has Now Recruited 100 Patients
PlaqueTec announced on November 12, 2026, that BIOPATTERN had recruited its 100th participant.
Recruitment is continuing toward a planned total of 300 patients.
The company expects recruitment to be completed in 2027.
Passing 100 patients is important because biomarker research depends heavily on having enough participants to distinguish meaningful biological patterns from normal variation.
The larger the dataset becomes, the greater the opportunity to identify reproducible disease subgroups.
Eight NHS Cardiac Centres Are Now Involved
The trial has also expanded to eight specialist cardiac centres across England.
The participating network includes:
- Royal Papworth Hospital, Cambridge;
- Norfolk and Norwich University Hospital;
- Royal Bournemouth Hospital;
- Bristol Heart Institute;
- St Bartholomew’s Hospital, London;
- Leeds General Infirmary;
- Blackpool Victoria Hospital;
- Queen Elizabeth Hospital Birmingham.
St Bartholomew’s and Leeds are recruiting patients, while Blackpool Victoria and Queen Elizabeth Birmingham have been set up to begin recruitment.
The expansion should help the study recruit a broader range of patients and accelerate progress toward the 300-participant target.
What Happens During the Study?
Participants already need to be scheduled for a coronary procedure.
BIOPATTERN does not send otherwise healthy people into the catheterization laboratory purely for research.
According to the Health Research Authority description of the study, enrolled patients undergo:
- intracoronary imaging;
- LBS blood sampling;
- analysis of disease-associated biomarkers;
- collection of clinical information.
The additional research procedures add approximately 30 minutes to the planned coronary procedure.
Participants are then followed with a telephone review 30 days later.
Researchers Are Measuring Thousands of Molecules
BIOPATTERN is not designed around one single biomarker.
Researchers are studying a broad range of biological signals.
According to PlaqueTec, the research program includes large-scale proteomic analysis alongside coronary imaging, genetic information and clinical data.
This allows investigators to examine thousands of biomolecules and determine whether particular combinations correspond with different types of coronary disease.
The resulting dataset is being incorporated into PlaqueTec’s BioCarta repository.
The longer-term aim is to identify distinct biological subgroups of patients.
Two Patients With Similar Plaques May Have Different Biology
This is the central precision-medicine hypothesis.
Two people can both have coronary artery disease but may not necessarily have the same biological processes driving it.
For example, one patient’s disease might be dominated by a particular inflammatory pathway.
Another may have a different pattern involving:
- immune signaling;
- lipid metabolism;
- vascular biology;
- tissue remodeling.
If these differences can be identified reliably, researchers may eventually be able to divide coronary disease into biologically defined subtypes.
Those subtypes are sometimes called endotypes.
Could Heart Disease Become More Like Precision Oncology?
Cancer medicine increasingly relies on molecular profiling.
Two tumors occurring in the same organ may receive different treatments because their mutations or molecular characteristics differ.
BIOPATTERN is exploring whether cardiovascular disease could move in a similar direction.
Instead of treating every patient with broadly similar therapies, future treatment might potentially be guided by the biological mechanisms active in a particular patient’s arteries.
That could help researchers identify:
- new drug targets;
- patient groups more likely to respond to specific treatments;
- biomarkers for clinical trials;
- more personalized cardiovascular strategies.
However, this remains a research objective.
BIOPATTERN has not yet demonstrated that this approach improves outcomes.
Local Blood Sampling May Reveal Signals Missed in Peripheral Blood
The main scientific advantage of intracoronary sampling is proximity.
Imagine that an inflamed plaque releases a protein into the blood.
Near the plaque, the concentration may be relatively high.
As that protein travels through the circulation, it becomes mixed with the entire blood volume.
By the time blood is drawn from an arm vein, the local signal may be difficult to detect.
Sampling at the site of disease could potentially reveal those gradients.
This concept is sometimes referred to as measuring a trans-plaque biomolecular gradient.
The Technology Has Earlier Proof-of-Concept Work Behind It
BIOPATTERN builds on smaller previous studies of the Liquid Biopsy System.
Earlier investigations suggested that blood sampled directly from coronary arteries could reveal molecular differences associated with atherosclerotic plaques.
The current trial is intended to expand that approach substantially.
Rather than simply demonstrating that local coronary blood can be collected, researchers now want to build a larger biological map of disease.
The Trial Is Registered as NCT06259019
BIOPATTERN is a registered clinical study identified as NCT06259019.
The trial is listed as recruiting and evaluates the Liquid Biopsy System in patients with established coronary artery disease.
The study is sponsored by PlaqueTec and coordinated by the Papworth Trials Unit Collaboration.
Its primary purpose is to establish the performance of the device and determine whether it can help characterize different forms of coronary disease.
The Study Is Not Testing a New Heart Drug
This distinction is important.
BIOPATTERN is described as an interventional clinical study because participants undergo an additional device-based sampling procedure.
But it is not a drug-efficacy trial.
No experimental medication is being tested to determine whether it prevents heart attacks.
The intervention is the Liquid Biopsy System itself.
The trial aims to answer whether the device can reliably obtain useful biomolecular information directly from diseased coronary arteries.
No Heart-Attack Prediction Test Has Been Proven Yet
It would also be premature to describe the LBS as a test that predicts which plaque will rupture.
BIOPATTERN has not yet established that.
The study has not announced evidence showing that the system can:
- predict an individual heart attack;
- identify exactly which plaque will rupture;
- reduce cardiovascular mortality;
- determine treatment automatically;
- improve long-term outcomes.
Such claims would require further prospective validation.
The current project is creating the biological foundation required before those questions can be properly tested.
Why Residual Cardiovascular Risk Matters
Modern cardiovascular treatment has dramatically reduced heart-attack risk.
Statins lower LDL cholesterol.
Antiplatelet drugs help prevent dangerous clots.
Blood-pressure medication reduces vascular strain.
Yet some patients continue to experience major events despite good treatment.
This suggests that important disease pathways remain incompletely addressed.
Inflammation is one example.
Large cardiovascular trials have already shown that targeting inflammation can reduce cardiovascular risk in selected circumstances, demonstrating that cholesterol is not the only biological process involved in atherosclerosis.
BIOPATTERN takes this idea further by asking whether individual patients may have different dominant disease pathways.
The Study Could Help Drug Development
One potential benefit may come before personalized treatment reaches everyday clinics.
Drug developers often test cardiovascular medicines in large groups of patients.
If only one biological subgroup responds strongly to the therapy, that effect can become diluted when all patients are analyzed together.
A biomarker platform capable of identifying relevant subgroups could potentially improve clinical-trial design.
Researchers could select patients whose disease biology matches the mechanism targeted by a particular drug.
This could make it easier to determine whether experimental treatments truly work.
The 100-Patient Milestone Is Important, but It Is Not a Result
The latest announcement should therefore be interpreted correctly.
Reaching 100 participants demonstrates:
- continued recruitment;
- successful expansion across NHS centres;
- growing availability of intracoronary biological samples;
- progress toward the 300-patient goal.
It does not demonstrate clinical efficacy.
The important scientific results will come when researchers analyze whether the local biomolecular patterns are reproducible, biologically meaningful and associated with distinct forms of disease.
Independent Ethical Review Has Been Completed
The BIOPATTERN research application received a favourable opinion from the North of Scotland Research Ethics Committee 1.
The Health Research Authority record identifies PlaqueTec as the sponsor and Stephen Hoole as the study contact and chief investigator.
The trial is coordinated through the Papworth Trials Unit Collaboration.
These details provide independent confirmation that BIOPATTERN is a formally registered clinical research study rather than simply a company development program.
What Could Happen If the Approach Works?
If researchers successfully identify reproducible coronary-disease endotypes, several future paths become possible.
Scientists could investigate whether the molecular signatures:
- predict cardiovascular events;
- correspond with plaque instability;
- reveal new therapeutic targets;
- identify patients for specific drugs;
- improve enrollment in cardiovascular trials.
Each of those possibilities would require additional validation.
A biomarker discovered during BIOPATTERN would not automatically become a clinical test.
It would need to be reproduced and shown to provide meaningful information beyond existing cardiovascular assessments.
Why This Research Matters
Coronary artery disease has traditionally been treated largely according to broad clinical risk.
That approach has saved millions of lives.
But atherosclerosis is biologically complex.
The disease involves interactions between:
- lipids;
- immune cells;
- inflammation;
- vascular cells;
- metabolism;
- genetics.
BIOPATTERN asks whether measuring those processes directly at the coronary plaque can reveal information that conventional blood tests miss.
The trial’s 100-patient milestone and expansion to eight NHS centres mark important progress toward answering that question.
But the larger promise, personalized treatment based on the biology of each patient’s coronary disease, remains to be proven.
For now, BIOPATTERN should be viewed as a major biomarker-discovery and precision-cardiology research project, rather than a new diagnostic test already ready for routine clinical practice.
